Clinical Trials for Lupus (SLE)
Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease in which the immune system attacks healthy tissue throughout the body. It can affect the skin, joints, kidneys, heart, lungs, and nervous system. Managing lupus is highly individual, and finding the right treatment can take time and trial.
Clinical trials for lupus are active and have been growing significantly in recent years, driven by a much better scientific understanding of the immune pathways involved. New biologics, small molecules, and combination strategies are all being studied.
According to the Lupus Foundation of America, approximately 1.5 million Americans -- and many more worldwide -- live with lupus.
What Types of Trials Are Available?
B-cell depletion trials study agents like belimumab (Benlysta) and newer anti-CD20 antibodies, building on the mechanisms already approved for lupus. Type I interferon pathway trials are among the most active areas in lupus research. Several drugs targeting the interferon pathway have shown promise in reducing flares, and trials are advancing these approaches. CAR-T trials for severe refractory lupus represent a new frontier. Early data from Phase 1 trials has shown significant responses, including drug-free remissions, in people with severe disease. These are conducted at specialized centers. Kidney-focused trials (lupus nephritis) specifically address renal involvement, which is one of the most serious complications of lupus. Voclosporin (Lupkynis) and belimumab have been approved for lupus nephritis; trials are studying additional agents and combination regimens.Search ClinicalTrials.gov for currently recruiting trials.
Am I Eligible?
Common eligibility factors for lupus trials include:
- Confirmed SLE diagnosis meeting ACR or EULAR criteria
- Active disease (SLEDAI score above a minimum threshold)
- Specific organ involvement (some trials focus on lupus nephritis or specific manifestations)
- Prior treatment history with hydroxychloroquine, corticosteroids, or immunosuppressants
- Stable medications (most trials require stable background therapy for a period before enrollment)
- No current serious infections or active malignancy
Talk to your rheumatologist to evaluate your current disease activity and treatment history against trial criteria. Talk to your doctor before making any decisions about your treatment.
What If My Insurance Denied My Medication?
Specialty medications for lupus -- including belimumab (Benlysta), anifrolumab (Saphnelo), and voclosporin (Lupkynis) -- are expensive and often require prior authorization. Denials are not uncommon, especially for newer agents.
If your rheumatologist has recommended a biologic and your insurance has denied it, you have the right to appeal. While that process moves forward, a clinical trial studying a similar or newer mechanism may offer access to treatment. This is a legitimate and often well-supported path.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Are clinical trials for lupus (SLE) free?
In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.
How do I find lupus (SLE) trials near me?
The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.
Can I join a trial after being denied Benlysta or Saphnelo?
Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Benlysta or Saphnelo or similar medications.